There is no specific treatment or approved drug for the treatment of HCM. A septal myectomy is an open-heart procedure in which the surgeon removes part of the thickened, overgrown septum between the ventricles. Removing part of this overgrown muscle improves blood flow and reduces mitral regurgitation.

 

A septal myectomy may be recommended if medications don’t relieve the symptoms. Most people who have a myectomy have no further symptoms. Septal myectomy is available only in medical centers that specialize in the treatment of hypertrophic cardiomyopathy.

 

Septal ablation is another treatment, in which a small portion of the thickened heart muscle is destroyed by injecting alcohol through a long, thin tube (catheter) into the artery supplying blood to that area. This procedure may improve the symptoms. To redress the current issues, the companies are currently working toward this indication to meet the needs of the current Hypertrophic Cardiomyopathy Treatment market

 

Pipeline drugs in clinical development are designed to address this unmet need in HCM treatment. The other factors that shall further expedite the growth of the HCM market include increasing the morbidity rate of HCM and increasing awareness about available treatments during the forecast period (2021–2030). A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hypertrophic Cardiomyopathy.

 

Extensive research and development activities of pharmaceutical companies for developing the therapies for HCM will significantly impact the market. The expected launch of Mavacamten (Bristol Myers Squibb) CK-274 (Cytokinetics), and LCZ-696 (Novartis) shall fuel the growth of the market during the forecast period, i.e., 2021–2030.

 

The dynamics of the HCM market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world. Key players in the therapeutic market of HCM at the global level are MyoKardia (now acquired by Bristol Myers Squibb), Cytokinetics, Novartis, Celltrion, etc. The expected launch of emerging therapy, such as Mavacamten, CK-274, CT-G20 will significantly impact the HCM market during the forecast period (2021– 2030).

 

Other therapies that are used for the treatment of HOCM include- Defibrillator therapy, Dual-chamber pacing, Biventricular pacing, and Heart Transplantation. Out of these, Defibrillator therapy is the only non-surgical therapy proven to reduce mortality in HCM patients when used in patients with appropriate risk. It is widely accepted that internal cardioverter defibrillator (ICD) placement is warranted for secondary prevention in patients who have survived ventricular fibrillation or ventricular tachycardia arrest. However, the question of which HCM patients warrant primary prevention using ICD remains an area of intense study.

 

There are many therapies that are being used for the management of the HCM, but they often are ineffective and cause severe adverse effects. These therapies give only symptomatic treatment. Due to its relative rarity and the complexity of its clinical symptoms, patients with HCM require continuous monitoring. Symptomatic treatment of patients with HNCM corresponds to the specific treatment of heart failure. So, there is a significant need for drug therapies that can treat the root cause of HCM.

 

Original Source:- Hypertrophic Cardiomyopathy Market Research Report